10x Genomics Quarterly Balance Sheets Chart
Quarterly
|
Annual
10x Genomics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||
| cash and cash equivalents | 397,712,000 | 377,061,000 | 344,067,000 | 398,159,000 | 379,824,000 | 355,781,000 | 359,284,000 | 311,264,000 | 325,879,000 | 332,320,000 | 219,746,000 | 233,951,000 | 274,187,000 | 312,487,000 | 587,447,000 | 600,440,000 | 621,958,000 | 617,195,000 | 768,773,000 | 339,840,000 | 372,428,000 | 424,166,000 | 427,436,000 |
| marketable securities | 49,549,000 | 49,844,000 | 49,335,000 | 269,000 | 16,033,000 | 29,411,000 | 45,643,000 | 65,506,000 | 85,970,000 | 210,238,000 | 218,435,000 | 225,546,000 | 226,836,000 | ||||||||||
| accounts receivable | 49,977,000 | 52,549,000 | 87,862,000 | 83,525,000 | 91,178,000 | 91,305,000 | 114,832,000 | 103,847,000 | 87,685,000 | 77,940,000 | 104,211,000 | 83,549,000 | 76,204,000 | 76,526,000 | 85,254,000 | 78,430,000 | 59,680,000 | 57,408,000 | 36,026,000 | 22,726,000 | 30,851,000 | 33,371,000 | 26,150,000 |
| other receivables | 69,090,000 | ||||||||||||||||||||||
| inventory | 68,968,000 | 74,710,000 | 83,107,000 | 94,050,000 | 88,272,000 | 83,189,000 | 73,706,000 | 80,917,000 | 83,687,000 | 82,307,000 | 81,629,000 | 78,629,000 | 70,646,000 | 63,697,000 | 59,966,000 | 51,141,000 | 44,087,000 | 38,507,000 | 25,118,000 | 21,758,000 | 19,357,000 | 15,270,000 | 13,305,000 |
| prepaid expenses and other current assets | 20,365,000 | 25,566,000 | 20,016,000 | 18,159,000 | 19,612,000 | 20,785,000 | 18,789,000 | 20,177,000 | 18,683,000 | 20,857,000 | 16,578,000 | 14,350,000 | 19,141,000 | 17,762,000 | 13,896,000 | 14,065,000 | 13,298,000 | 14,442,000 | 11,083,000 | 9,411,000 | 7,096,000 | 8,033,000 | 7,253,000 |
| total current assets | 655,661,000 | 579,730,000 | 584,387,000 | 593,893,000 | 579,155,000 | 567,093,000 | 596,022,000 | 562,348,000 | 582,940,000 | 601,894,000 | 635,035,000 | 629,422,000 | 666,232,000 | 697,335,000 | 747,591,000 | 744,104,000 | 757,174,000 | 745,716,000 | 900,451,000 | 451,584,000 | 429,732,000 | 480,840,000 | 474,144,000 |
| property and equipment | 239,710,000 | 246,087,000 | 252,648,000 | 258,759,000 | 263,285,000 | 269,486,000 | 279,571,000 | 285,008,000 | 284,913,000 | 292,106,000 | 289,328,000 | 257,694,000 | 223,001,000 | 190,200,000 | 169,492,000 | 142,589,000 | 122,329,000 | 107,313,000 | 65,111,000 | 55,930,000 | 52,384,000 | 48,821,000 | 46,840,000 |
| operating lease right-of-use assets | 62,700,000 | 55,577,000 | 57,290,000 | 59,579,000 | 60,872,000 | 62,850,000 | 65,361,000 | 69,192,000 | 71,049,000 | 74,738,000 | 69,882,000 | 71,095,000 | 73,425,000 | 75,680,000 | 60,918,000 | 60,715,000 | 54,125,000 | 56,353,000 | 45,379,000 | 43,137,000 | 44,048,000 | ||
| goodwill | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | 4,511,000 | |||||
| intangible assets | 14,714,000 | 15,192,000 | 15,671,000 | 16,149,000 | 16,658,000 | 16,129,000 | 16,616,000 | 21,833,000 | 22,290,000 | 22,948,000 | 22,858,000 | 23,493,000 | 24,128,000 | 24,764,000 | 25,397,000 | ||||||||
| other noncurrent assets | 2,674,000 | 2,296,000 | 4,129,000 | 4,903,000 | 5,187,000 | 2,844,000 | 3,062,000 | 2,674,000 | 20,461,000 | 12,859,000 | 2,392,000 | 2,901,000 | 3,199,000 | 3,163,000 | 3,319,000 | ||||||||
| total assets | 979,970,000 | 903,393,000 | 918,636,000 | 937,794,000 | 929,668,000 | 922,913,000 | 965,143,000 | 948,540,000 | 989,638,000 | 1,014,030,000 | 1,028,980,000 | 996,207,000 | 1,001,591,000 | 1,003,251,000 | 1,018,826,000 | 990,572,000 | 977,579,000 | 954,033,000 | 1,042,544,000 | 582,802,000 | 610,384,000 | 605,923,000 | 572,815,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||
| accounts payable | 15,938,000 | 10,068,000 | 12,909,000 | 26,210,000 | 21,248,000 | 20,216,000 | 15,738,000 | 18,836,000 | 23,124,000 | 29,317,000 | 21,599,000 | 21,594,000 | 26,731,000 | 18,956,000 | 17,351,000 | 17,037,000 | 16,181,000 | 15,578,000 | 9,490,000 | 9,916,000 | 13,505,000 | 13,028,000 | 11,959,000 |
| accrued compensation and related benefits | 26,102,000 | 21,957,000 | 33,615,000 | 30,080,000 | 20,078,000 | 20,670,000 | 30,105,000 | 28,477,000 | 22,372,000 | 17,574,000 | 32,675,000 | 28,214,000 | 23,505,000 | 18,324,000 | 31,626,000 | 27,182,000 | 21,113,000 | 16,820,000 | 11,189,000 | 10,276,000 | 18,623,000 | 12,394,000 | 7,850,000 |
| accrued expenses and other current liabilities | 39,063,000 | 45,483,000 | 41,165,000 | 37,770,000 | 42,437,000 | 42,424,000 | 56,648,000 | 36,256,000 | 34,088,000 | 47,386,000 | 59,779,000 | 61,989,000 | 53,222,000 | 44,095,000 | 50,909,000 | 46,187,000 | 36,157,000 | 32,665,000 | 38,583,000 | 19,442,000 | 20,093,000 | 24,448,000 | 14,267,000 |
| deferred revenue | 21,449,000 | 20,949,000 | 20,658,000 | 17,760,000 | 16,436,000 | 14,296,000 | 13,150,000 | 11,143,000 | 9,217,000 | 8,530,000 | 7,867,000 | 6,665,000 | 6,473,000 | 5,434,000 | 5,340,000 | 5,505,000 | 5,274,000 | 4,481,000 | |||||
| operating lease liabilities | 9,669,000 | 9,443,000 | 9,286,000 | 9,415,000 | 10,820,000 | 11,127,000 | 11,521,000 | 10,005,000 | 9,286,000 | 9,199,000 | 9,037,000 | 8,393,000 | 7,977,000 | 7,637,000 | 5,131,000 | 4,464,000 | 4,905,000 | 6,156,000 | 4,976,000 | 3,938,000 | 3,453,000 | ||
| total current liabilities | 112,221,000 | 107,900,000 | 117,633,000 | 121,235,000 | 111,019,000 | 108,733,000 | 127,162,000 | 104,717,000 | 98,087,000 | 112,006,000 | 130,957,000 | 126,855,000 | 117,908,000 | 94,446,000 | 110,357,000 | 100,375,000 | 113,126,000 | 120,549,000 | 145,571,000 | 122,180,000 | 59,068,000 | 63,049,000 | 48,236,000 |
| operating lease liabilities, noncurrent | 77,075,000 | 70,631,000 | 73,327,000 | 76,461,000 | 78,662,000 | 81,049,000 | 83,849,000 | 88,468,000 | 90,331,000 | 92,843,000 | 86,139,000 | 87,833,000 | 91,040,000 | 93,538,000 | 76,847,000 | 75,735,000 | 65,917,000 | 66,344,000 | 56,618,000 | 55,228,000 | 56,166,000 | ||
| deferred revenue, noncurrent | 11,270,000 | 12,569,000 | 12,513,000 | 12,349,000 | 11,358,000 | 9,787,000 | 8,814,000 | 834,000 | 1,202,000 | ||||||||||||||
| other noncurrent liabilities | 6,125,000 | 5,398,000 | 5,029,000 | 4,945,000 | 4,571,000 | 4,510,000 | 4,275,000 | 10,139,000 | 7,919,000 | 6,796,000 | 6,141,000 | 5,727,000 | 9,127,000 | 8,582,000 | 8,240,000 | 8,427,000 | 8,136,000 | 8,866,000 | 4,052,000 | 2,902,000 | 1,545,000 | 1,091,000 | 951,000 |
| total liabilities | 206,691,000 | 196,498,000 | 208,502,000 | 214,990,000 | 205,610,000 | 204,079,000 | 224,100,000 | 203,324,000 | 196,337,000 | 211,645,000 | 223,237,000 | 220,415,000 | 218,075,000 | 196,566,000 | 201,258,000 | 190,351,000 | 192,993,000 | 201,573,000 | 217,464,000 | 191,533,000 | 201,316,000 | 185,840,000 | 151,367,000 |
| commitments and contingencies | |||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||
| preferred stock | |||||||||||||||||||||||
| common stock | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 |
| additional paid-in capital | 2,239,924,000 | 2,208,665,000 | 2,177,672,000 | 2,140,789,000 | 2,106,752,000 | 2,063,657,000 | 2,025,890,000 | 1,981,359,000 | 1,936,750,000 | 1,883,930,000 | 1,839,397,000 | 1,793,388,000 | 1,757,671,000 | 1,714,860,000 | 1,680,865,000 | 1,644,897,000 | 1,612,227,000 | 1,569,059,000 | 1,214,655,000 | 714,630,000 | 692,617,000 | 682,494,000 | 676,839,000 |
| accumulated deficit | -1,466,867,000 | -1,501,405,000 | -1,467,047,000 | -1,418,019,000 | -1,382,266,000 | -1,344,369,000 | -1,284,420,000 | -1,235,468,000 | -1,142,482,000 | -1,080,068,000 | -1,029,321,000 | -1,012,106,000 | -970,192,000 | -905,734,000 | -863,321,000 | -844,872,000 | -827,701,000 | -816,649,000 | -389,525,000 | -323,677,000 | -283,510,000 | -262,367,000 | -255,233,000 |
| accumulated other comprehensive income | 220,000 | 32,000 | -4,335,000 | -5,492,000 | -3,965,000 | -2,443,000 | |||||||||||||||||
| total stockholders’ equity | 773,279,000 | 706,895,000 | 710,134,000 | 722,804,000 | 724,058,000 | 718,834,000 | 741,043,000 | 745,216,000 | 793,301,000 | 802,385,000 | 805,743,000 | 775,792,000 | 783,516,000 | 806,685,000 | 817,568,000 | 800,221,000 | 784,586,000 | 752,460,000 | 825,080,000 | 391,269,000 | 409,068,000 | 420,083,000 | 421,448,000 |
| total liabilities and stockholders’ equity | 979,970,000 | 903,393,000 | 918,636,000 | 937,794,000 | 929,668,000 | 922,913,000 | 965,143,000 | 948,540,000 | 989,638,000 | 1,014,030,000 | 1,028,980,000 | 996,207,000 | 1,001,591,000 | 1,003,251,000 | 1,018,826,000 | 990,572,000 | 977,579,000 | 954,033,000 | 1,042,544,000 | 582,802,000 | 610,384,000 | ||
| accumulated other comprehensive loss | -367,000 | -493,000 | -430,000 | -456,000 | -429,000 | -677,000 | -969,000 | -1,479,000 | -52,000 | -41,000 | -46,000 | -160,000 | |||||||||||
| stockholders' equity: | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of december 31, 2024 and 2023 | |||||||||||||||||||||||
| restricted cash | 500,000 | 1,500,000 | 2,500,000 | 2,633,000 | 508,000 | 508,000 | 27,000 | 1,028,000 | 28,000 | 18,151,000 | 18,164,000 | 59,451,000 | 57,849,000 | 59,475,000 | 52,327,000 | 50,053,000 | |||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of december 31, 2023 and 2022 | |||||||||||||||||||||||
| accrued license fee, noncurrent | 5,814,000 | 5,814,000 | 5,814,000 | 5,814,000 | 11,223,000 | 11,223,000 | 11,223,000 | 16,251,000 | |||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of december 31, 2022 and december 31, 2021 | |||||||||||||||||||||||
| accrued contingent liabilities | 29,496,000 | 44,849,000 | 77,558,000 | 75,176,000 | 73,314,000 | 68,658,000 | 62,501,000 | ||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of december 31, 2021 and december 31, 2020 | |||||||||||||||||||||||
| accumulated other comprehensive gain | 22,000 | 194,000 | 58,000 | 48,000 | 314,000 | ||||||||||||||||||
| other non-current assets | 30,056,000 | 30,841,000 | |||||||||||||||||||||
| other assets | 31,542,000 | 26,129,000 | 26,150,000 | 24,745,000 | 23,935,000 | 1,778,000 | |||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of march 31, 2021 and december 31, 2020 | |||||||||||||||||||||||
| term loans, current portion | 9,882,000 | 7,383,000 | |||||||||||||||||||||
| deferred revenue, current | 3,775,000 | 3,432,000 | 3,394,000 | 3,297,000 | 3,082,000 | ||||||||||||||||||
| term loans, noncurrent portion | 19,837,000 | 22,307,000 | |||||||||||||||||||||
| deferred rent, noncurrent | 16,120,000 | 16,170,000 | |||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of september 30, 2020 and december 31, 2019 | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of june 30, 2020 and december 31, 2019 | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of march 31, 2020 and december 31, 2019 | |||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||
| convertible preferred stock, 0.00001 par value, no shares authorized and no shares issued and outstanding as of december 31, 2019; 67,904,871 shares authorized and 67,704,278 shares issued and outstanding as of december 31, 2018; aggregate liquidation preference of 242,588 as of december 31, 2018 | |||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of december 31, 2019; no shares authorized, issued or outstanding as of december 31, 2018 | |||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 605,923,000 | 572,815,000 | |||||||||||||||||||||
| accrued legal expenses | 3,695,000 | ||||||||||||||||||||||
| convertible preferred stock, 0.00001 par value, no shares authorized and no shares issued and outstanding as of september 30, 2019; 67,904,871 shares authorized and 67,704,278 shares issued and outstanding as of december 31, 2018; aggregate liquidation preference of 242,588 as of december 31, 2018 | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of september 30, 2019 and december 31, 2018 |
We provide you with 20 years of balance sheets for 10x Genomics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 10x Genomics. Explore the full financial landscape of 10x Genomics stock with our expertly curated balance sheets.
The information provided in this report about 10x Genomics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.